Cargando…
Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model
Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor st...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591884/ https://www.ncbi.nlm.nih.gov/pubmed/28928654 http://dx.doi.org/10.3389/fphar.2017.00558 |
_version_ | 1783262802735005696 |
---|---|
author | Pizzino, Gabriele Irrera, Natasha Galfo, Federica Oteri, Giacomo Atteritano, Marco Pallio, Giovanni Mannino, Federica D’Amore, Angelica Pellegrino, Enrica Aliquò, Federica Anastasi, Giuseppe P. Cutroneo, Giuseppina Squadrito, Francesco Altavilla, Domenica Bitto, Alessandra |
author_facet | Pizzino, Gabriele Irrera, Natasha Galfo, Federica Oteri, Giacomo Atteritano, Marco Pallio, Giovanni Mannino, Federica D’Amore, Angelica Pellegrino, Enrica Aliquò, Federica Anastasi, Giuseppe P. Cutroneo, Giuseppina Squadrito, Francesco Altavilla, Domenica Bitto, Alessandra |
author_sort | Pizzino, Gabriele |
collection | PubMed |
description | Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor stimulation for treating GIO was tested. In a preventive study GIO was induced in Sprague-Dawley rats by methylprednisolone (MP) for 60 days. Animals were randomly assigned to receive polydeoxyribonucleotide (PDRN), an adenosine A2 receptor agonist, or PDRN and DMPX (3,7-dimethyl-1-propargylxanthine, an A(2) antagonist), or vehicle (0.9% NaCl). Another set of animals was used for a treatment study, following the 60 days of MP-induction rats were randomized to receive (for additional 60 days) PDRN, or PDRN and DMPX (an adenosine A2 receptor antagonist), or zoledronate (as control for gold standard treatment), or vehicle. Control animals were administered with vehicle for either 60 or 120 days. Femurs were analyzed after treatments for histology, imaging, and breaking strength analysis. MP treatment induced severe bone loss, the concomitant use of PDRN prevented the developing of osteoporosis. In rats treated for 120 days, PDRN restored bone architecture and bone strength; increased b-ALP, osteocalcin, osteoprotegerin and stimulated the Wnt canonical and non-canonical pathway. Zoledronate reduced bone resorption and ameliorated the histological features, without significant effects on bone formation. Our results suggest that adenosine receptor stimulation might be useful for preventing and treating GIO. |
format | Online Article Text |
id | pubmed-5591884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55918842017-09-19 Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model Pizzino, Gabriele Irrera, Natasha Galfo, Federica Oteri, Giacomo Atteritano, Marco Pallio, Giovanni Mannino, Federica D’Amore, Angelica Pellegrino, Enrica Aliquò, Federica Anastasi, Giuseppe P. Cutroneo, Giuseppina Squadrito, Francesco Altavilla, Domenica Bitto, Alessandra Front Pharmacol Pharmacology Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor stimulation for treating GIO was tested. In a preventive study GIO was induced in Sprague-Dawley rats by methylprednisolone (MP) for 60 days. Animals were randomly assigned to receive polydeoxyribonucleotide (PDRN), an adenosine A2 receptor agonist, or PDRN and DMPX (3,7-dimethyl-1-propargylxanthine, an A(2) antagonist), or vehicle (0.9% NaCl). Another set of animals was used for a treatment study, following the 60 days of MP-induction rats were randomized to receive (for additional 60 days) PDRN, or PDRN and DMPX (an adenosine A2 receptor antagonist), or zoledronate (as control for gold standard treatment), or vehicle. Control animals were administered with vehicle for either 60 or 120 days. Femurs were analyzed after treatments for histology, imaging, and breaking strength analysis. MP treatment induced severe bone loss, the concomitant use of PDRN prevented the developing of osteoporosis. In rats treated for 120 days, PDRN restored bone architecture and bone strength; increased b-ALP, osteocalcin, osteoprotegerin and stimulated the Wnt canonical and non-canonical pathway. Zoledronate reduced bone resorption and ameliorated the histological features, without significant effects on bone formation. Our results suggest that adenosine receptor stimulation might be useful for preventing and treating GIO. Frontiers Media S.A. 2017-09-05 /pmc/articles/PMC5591884/ /pubmed/28928654 http://dx.doi.org/10.3389/fphar.2017.00558 Text en Copyright © 2017 Pizzino, Irrera, Galfo, Oteri, Atteritano, Pallio, Mannino, D’Amore, Pellegrino, Aliquò, Anastasi, Cutroneo, Squadrito, Altavilla and Bitto. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Pizzino, Gabriele Irrera, Natasha Galfo, Federica Oteri, Giacomo Atteritano, Marco Pallio, Giovanni Mannino, Federica D’Amore, Angelica Pellegrino, Enrica Aliquò, Federica Anastasi, Giuseppe P. Cutroneo, Giuseppina Squadrito, Francesco Altavilla, Domenica Bitto, Alessandra Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model |
title | Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model |
title_full | Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model |
title_fullStr | Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model |
title_full_unstemmed | Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model |
title_short | Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model |
title_sort | adenosine receptor stimulation improves glucocorticoid-induced osteoporosis in a rat model |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591884/ https://www.ncbi.nlm.nih.gov/pubmed/28928654 http://dx.doi.org/10.3389/fphar.2017.00558 |
work_keys_str_mv | AT pizzinogabriele adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT irreranatasha adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT galfofederica adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT oterigiacomo adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT atteritanomarco adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT palliogiovanni adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT manninofederica adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT damoreangelica adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT pellegrinoenrica adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT aliquofederica adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT anastasigiuseppep adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT cutroneogiuseppina adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT squadritofrancesco adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT altavilladomenica adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel AT bittoalessandra adenosinereceptorstimulationimprovesglucocorticoidinducedosteoporosisinaratmodel |